RoundTable将收购BD眼科系统业务，以及医疗外科系统业务的一部分，包括手术刀片、病危护理以及加长留置导管产品系列

Contact: Colleen T. White
Corporate Communications
(201) 847-5369
Email: colleen_white@bd.com

Sherry L.  Bertner
Investor Relations
(201) 847-5453

Franklin Lakes, NJ (June 8, 2010) – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it has signed agreements to sell certain assets of its BD Medical segment, including the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit, to RoundTable Healthcare Partners, an operating-oriented private equity firm focused on the healthcare industry based in Lake Forest, Illinois, and two of its portfolio companies, Argon Medical Devices, Inc. and Aspen Surgical Products, Inc. The financial terms of the agreements were not disclosed.

“This sale will enable BD to focus resources and management attention on opportunities which are a preferred strategic fit with the BD Medical strategy, which focuses on parenteral medication delivery,” stated Edward J. Ludwig, Chairman and Chief Executive Officer. “We are pleased that we found in RoundTable a buyer committed to the success of these sound businesses, which provide value to customers.”

The transaction is expected to be completed by the end of BD’s fourth fiscal quarter 2010 following the satisfaction of customary closing conditions, including consultations and regulatory approvals.

BD expects to record a gain in its fourth fiscal quarter 2010 results in connection with the planned sale. Asset groups, with estimated revenues of approximately $200 million and estimated earnings per share of $0.20 to $0.24 for the full fiscal year 2010, have been classified as discontinued operations as will be reflected in the Company’s third fiscal quarter 2010 financial statements.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.